• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Mortality Risk High for Some Gleason Grade 1 Prostate Cancer Patients

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 1, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, Aug. 1, 2024 -- For patients with Gleason Grade Group (GGG) 1 prostate cancer (PC), those with percentage positive biopsies (PPB) >50 percent or prostate-specific antigen (PSA) >20 ng/mL have a significantly increased risk for adverse outcomes, according to a study published online July 2 in European Urology Oncology.

Derya Tilki, M.D., from University Hospital Hamburg-Eppendorf in Germany, and colleagues examined the association of clinical factors at presentation with the presence of unsampled high-risk PC and PC-specific mortality (PCSM) and all-cause mortality following radical prostatectomy in a study population composed of 10,228 patients treated for GGG1 PC diagnosed via transrectal ultrasound-guided systematic biopsy (SBx) or combined biopsy (CBx).

The researchers found that PPB >50 percent and PSA >20 ng/mL were significantly associated with a higher risk for adverse pathology, regardless of biopsy approach (SBx: adjusted odds ratios [aORs], 1.71 and 3.49; CBx: aORs, 1.81 and 2.82, respectively) and with early PSA failure (SBx: adjusted hazard ratios [aHRs], 1.54 and 4.37; CBx: aHRs, 2.88 and 7.81, respectively). In the SBx group, PPB >50 percent and PSA >20 ng/mL were also associated with a higher risk for PCSM (aHRs, 2.56 and 3.71, respectively) and with all-cause mortality (aHRs, 1.47 and 2.00, respectively).

"For patients with GGG1 who are at heightened risk, we should continue to call their diagnosis cancer and we should report it back to their physician so that they can act on this information," senior author Anthony V. D'Amico, M.D., Ph.D., from Brigham and Women's Hospital in Boston, said in a statement.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted August 2024

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.